|
News For AZN;MEDI;NPSP;CELG;PRXL;PFE;ALKS;TEVA;ACOR From The Last 14 Days Check below for free stories on AZN;MEDI;NPSP;CELG;PRXL;PFE;ALKS;TEVA;ACOR the last two weeks. |
|
|
| May 24, 2013 |
| 16:07 EDT |  | AZN | Actavis confirms appeal court issues injunction related to Resupules
Actavis (ACT) confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca (AZN) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort Respules 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the court. |
|
| 10:04 EDT |  | ALKS | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information |
|
| 08:36 EDT | | ALKS | Alkermes downgraded to Sell from Neutral at MKM Partners
Subscribe for More Information |
|
| 08:22 EDT |  | AZN | Leerink's biotech analysts hold an analyst/industry conference call
Subscribe for More Information |
|
| 07:20 EDT |  | CELG | Celgene, Gilead, and Biogen could go much higher, says Bernstein
Subscribe for More Information |
|
| May 23, 2013 |
| 07:37 EDT | | CELG | Celgene says FDA grants priority review for ABRAXANE sNDA
Subscribe for More Information |
|
| 07:08 EDT | | ALKS | Alkermes changes fiscal year end, sees 9-months EPS 61c-75c
Alkermes has changed its fiscal year-end from March 31 to Dec. 31 and outlined financial expectations for the nine-month period ending Dec. 31, 2013. Alkermes expects total revenues to range from $395M-$425M, and non-GAAP net income to range from $85M-$105M or 61c-75c per share, for the nine months ending Dec. 31, 2013. Following the change in the company’s financial year-end, the company expects total pro forma revenues for the calendar year ending Dec. 31, 2013, to range from $558M-$588M and expects pro forma non-GAAP net income for the calendar year ending Dec. 31, 2013, to range from $141M-$161M. |
|
| 07:03 EDT |  | ALKS | Alkermes reports Q4 EPS 40c, may not compare to consensus 17c
Reports Q4 revenue $163.4M, consensus $128.01M. Revenues for the quarter included $30.0M of intellectual property license revenue unrelated to key development programs. |
|
| May 22, 2013 |
| 16:23 EDT | | TEVA | Alexza Pharmaceuticals chief commercial officer to leave company
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
| |
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| May 21, 2013 |
| 17:59 EDT |  | NPSP | NPS Pharmaceuticals 6M share Secondary priced at $14.53
Subscribe for More Information |
|
| 10:00 EDT |  | PRXL | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 07:40 EDT | | PRXL | PAREXEL initiated with a Neutral at ISI Group
Subscribe for More Information |
|
| 07:34 EDT | | NPSP | UBS to host a conference
Subscribe for More Information |
|
| 07:16 EDT | | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
| |
|
|
|
|
